# The Mycobiome: A Neglected Component in the Microbiota-Gut-Brain Axis

R. Enaud, L. E. Vandenborght, N. Coron, T. Bazin, R. Prevel, T.

Schaeverbeke, P. Berger, M. Fayon, Thierry Lamireau, L. Delhaes

► To cite this version:

R. Enaud, L. E. Vandenborght, N. Coron, T. Bazin, R. Prevel, et al., The Mycobiome: A Neglected Component in the Microbiota-Gut-Brain Axis. Microorganisms, 2018, 6 (1), pp.22. 10.3390/microorganisms6010022. doi:10.3390/microorganisms6010022

HAL Id: hal-03164867

https://hal.science/hal-03164867

Submitted on 10 Mar 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Review

# The Mycobiome: A Neglected Component in the Microbiota-Gut-Brain Axis

Raphaël Enaud<sup>1,2,3,*</sup>, Louise-Eva Vandenborgh<sup>1,3,4</sup>, Noémie Coron<sup>1,2,3</sup>, Thomas Bazin<sup>1,2</sup>, Renaud Prevel<sup>1</sup>, Thierry Schaeverbeke<sup>1,2</sup>, Patrick Berger<sup>1,2,3</sup>, Michael Fayon<sup>1,2,3</sup>, Thierry Lamireau<sup>1,2 id</sup> and Laurence Delhaes<sup>1,2,3</sup>

Received: 5 February 2018; Accepted: 5 March 2018; Published: 9 March 2018

**Abstract:** In recent years, the gut microbiota has been considered as a full-fledged actor of the gut-brain axis, making it possible to take a new step in understanding the pathophysiology of both neurological and psychiatric diseases. However, most of the studies have been devoted to gut bacterial microbiota, forgetting the non-negligible fungal flora. In this review, we expose how the role of the fungal component in the microbiota-gut-brain axis is legitimate, through its interactions with both the host, especially with the immune system, and the gut bacteria. We also discuss published data that already attest to a role of the mycobiome in the microbiota-gut-brain axis, and the impact of fungi on clinical and therapeutic research.

**Keywords:** brain-gut axis; mycobiome; microbiome; dysbiosis; neurological disorders; psychiatric disorders; fungus

## 1. Introduction

It has long been accepted that the central nervous system (CNS) and the intestine are closely connected, as suggested by satiety sensations or visceral pains. However, the concept of “microbiome-gut-brain axis (-GBA)” has emerged very recently as a bidirectional communication system in which the digestive microbial flora, also known as the gut microbiome, play a key role [1]. Indeed, accumulated evidence suggests that the intestinal microbiome may modulate CNS activities, which may, in turn, have an impact on the intestinal microbiome [2]. Several studies on mice have illustrated this mutual dialogue well between the gut microbiome and the brain. On the one hand, mice elevated in a sterile environment have an increased anxiety-like behavior that can be reversed after gut colonization with a commensal microbiome [3,4]. On the other hand, the diversity of the gut microbiome is diminished in rodent maternal separation, a model of depression [5]. Lastly, the clinical efficacy of specific probiotic strains in human neuropsychiatric pathologies, such as anxiety or depression, strengthens the concept of the microbiome-GBA [6].

The gut microbiome is a rich and complex ecosystem composed of bacteria, archaea, viruses, fungi, protists, and (sometimes) helminths. The essential role of this ecosystem in host homeostasis,

<footnote n="1">¹ Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, FHU ACRONIM, University Bordeaux, 33000 Bordeaux, France; louise-eva.vandenborgh@genoscreen.fr (L.-E.V.); noemie.coron@chu-bordeaux.fr (N.C.); thomasbazin@club-internet.fr (T.B.); renaud.prevel@hotmail.fr (R.P.); thierry.schaeverbeke@chu-bordeaux.fr (T.S.); patrick.berger@chu-bordeaux.fr (P.B.); michael.fayon@chu-bordeaux.fr (M.F.); thierry.lamireau@chu-bordeaux.fr (T.L.); laurence.delhaes@chu-bordeaux.fr (L.D.)</footnote>

<footnote n="2">² Service d'Exploration Fonctionnelle Respiratoire, Service de Rhumatologie, Service de Gastrologie Adulte, Laboratoire de Parasitologie-Mycologie, CRCM Pédiatrique, Gastroentérologie et Nutrition Pédiatriques, Unité d'Hépatologie, CHU Bordeaux, 33000 Bordeaux, France</footnote>

<footnote n="3">³ INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, 33000 Bordeaux, France</footnote>

<footnote n="4">⁴ Genoscreen Society, 59000 Lille, France</footnote>

<footnote>* Correspondence: raphael.enaud@chu-bordeaux.fr</footnote>
including metabolic and immune functions, is now well demonstrated, as is its involvement
in the pathophysiology of digestive and extra-digestive disorders [7,8]. The development of
culture-independent techniques for identifying microorganisms, such as next-generation sequencing
(NGS), has improved our knowledge on the composition and dynamics of this ecosystem. However,
most studies have focused exclusively on the bacterial component, the dominant domain, neglecting
fungi and other minority kingdoms [9]. GBA illustrates this trend well since few studies integrate
fungal analysis. No review to date has been devoted to the role of intestinal fungi—also named gut
mycobiome—in the microbiome-GBA, despite the key role conferred to fungi in digestive diseases [10].

In this review, we summarize the recent findings on the gut mycobiome and its major interactions
with the host and the other digestive microorganisms in order to decipher both the existence and
the role of a mycobiome-gut-brain axis. Finally, we review the existing literature assessing the links
between fungi, the digestive ecosystem, and neurological or neuropsychiatric disorders.

## 2. Gut Mycobiome: State of the Art

Unlike the bacteria that inhabit our digestive tract, the human gut mycobiome has been poorly studied and characterized in healthy as well as in diseased individuals. Initially, the large-scale projects such as the National Institutes of Health's Human Microbiome Project (HMP) and Metagenomics of the Human Intestinal Tract (MetaHIT) Project were focused exclusively on the bacterial flora to characterize their composition and impact on human health and diseases [11,12]. Bacteria represent huge quantities of microorganisms that inhabit the intestinal mucosa whereas fungi represent a tiny part, estimated at less than 0.01% to 0.1% of genes in stool samples [13,14]. Furthermore, a large part of these fungi are difficult to culture in vitro or are uncultivable [14]. However, the NGS development has been valuable in revealing this poorly understood compartment of our whole microbiome [15]. The main steps of NGS mycobiome analysis are summarized in Table 1 [9,13,15–25].

Since fungi are ubiquitous in our environment—present in the air we breathe, in the food we eat, such as bread, cheese, beer or even in antibiotics—nobody is fungus-free [14,26,27]. Therefore, fungi have been recognized as an integral part of our commensal flora at different body sites (skin, lung, vagina, oral tract, and gut) [28,29]. In the digestive tract, fungi seem to colonize the gut shortly after birth [30,31]. Briefly, the fungal composition of gut flora is influenced by several factors such as age, host genetics, host immunity, diet, and medication [32,33], as well as the bacterial microbiome that also impacts the mycobiome through inter-kingdom interactions [33].

Despite a recent increased number of published data on the gut mycobiome, defining the healthy gut mycobiome is still difficult, especially regarding the high inter- and intra-volunteer variability of the mycobiome. In contrast with gut-associated bacteria, several studies have found a lack of stability in the gut mycobiome over time and low abundance and diversity [13,34]. To date, there is no consensus on the mycobiome "normobiosis," a term referring to a balanced composition of gut flora in healthy individuals (by contrast, a disruption of this balanced microbial composition of gut flora is named "dysbiosis"). In most studies, Ascomycota is by far the most prevalent fungus phylum in the gut, followed by Zygomycota (corresponding at the previous phylogenetic classification, now distributed among Glomeromycota and several subphyla incertae sedis, including Mucoromycotina, Entomophthoromycotina, Kickxellomycotina, and Zoopagomycotina) and Basidiomycota phyla [33–36]. Hallen-Adams and colleagues [37] have sequenced stool samples from 45 subjects and observed solely 72 operational taxonomic units (OTUs) assigned as fungal sequences, which is clearly less than bacterial abundance. These OTUs were distributed in two phyla (Ascomycota and Basidiomycota) and in ten classes of micromycetes. The most abundant fungi were *Candida tropicalis* and yeasts belonging to Dipodascaceae. Interestingly, gut fungi observed in this study included known human symbionts (*Candida*, *Cryptococcus*, *Malassezia*, and *Trichosporon* spp.), environmental fungi (*Cladosporium* sp.), and food-associated fungi (*Debaryomyces hansenii*, *Penicillium roqueforti*) [37]. These data reinforce the wide exposure of humans to molds throughout a person's life. Another NGS study identified 66 fungal genera within 96 stool samples
collected from 50 patients, of which 12 were healthy control patients [33]. *Saccharomyces* corresponded to the most prevalent genus followed by *Candida* and *Cladosporium*. A third study observed 75 fungal genera with *Saccharomyces*, *Candida*, and *Penicillium* being the most prevalent [38]. Recently, for the gut mycobiome, Nash and colleagues sequenced 317 stool samples from the American HMP project [13]. Gut-associated fungi in this healthy cohort were mainly composed of a high prevalence of *Saccharomyces*, *Candida*, and *Malassezia*, with *Saccharomyces cerevisiae*, *Malassezia restricta*, and *Candida albicans* being found in 96.8%, 88.3%, and 80.8% of the samples, respectively. Taking together these studies confirms the lower diversity of gut mycobiome in healthy subjects compared to the gut bacterial microbiome [13,33,37,38].

Even if the fungal component is a limited part of the gut ecosystem, it appears to be an essential player of the human microbiome. The increasing interest in gut mycobiome, its dysbiosis, and its role in the GBA is driven by recent data supporting its interactions with the host and the bacterial microbiome.

<table><caption>**Table 1.** Current metagenomic steps to analyze the mycobiome.</caption><thead><tr><td>Metagenomic Steps</td><td>Comments</td><td>References</td></tr></thead><tbody><tr><td>Extraction of fungal communities</td><td><ul><li>Fungus cell wall is difficult to lyse: mechanical cell disruption (bead beating) or enzymatic cell lysis (lyticase) are usually used; currently, there is no consensus adopted for mycobiome analysis.</li><li>Commercial kits are rarely optimized for fungal extraction</li></ul></td><td>[15–17]</td></tr><tr><td>Libraries preparation</td><td><ul><li>Metagenomic target debate: Either internal transcribed spacer (ITS1, ITS2) or 18S rDNA are used in mycobiome analysis. In the same study [11], ITS2 and 18S rRNA loci revealed similar results. While 18S primers were able to detect the non-fungal eukaryotic flora, shotgun metagenomics sequencing was in agreement with results from ITS2 sequencing.</li><li>Specific NGS method is able to distinguish living and dead cells using pre-treatment with propidium monoazide (PMA)</li></ul></td><td>[8,12,16,18–20]</td></tr><tr><td>High-throughput sequencing</td><td><ul><li>Usual sequencing platforms: Illumina (Miseq), Ion Torrent (PGM))</li><li>Uneven ITS length among fungal species may impact species abundance in case of targeted amplicon sequencing</li><li>Whole genome sequencing (shotgun metagenomic) may offer both accurate taxonomic assignments and functional data at gene levels but requires higher cost and intensive bioinformatic analysis</li></ul></td><td>[16,18,20,21]</td></tr><tr><td>Bioinformatics analysis</td><td><ul><li>Preprocessing, OTU picking, and taxonomic classification: lack of standardization even if QIIME (Quantitative Insights Into Microbial Ecology), an open-source bioinformatic pipeline, is one of the most used</li><li>Quality and completeness of fungal databases lead to different proportions of unassigned sequences (17% of the total OTUs in some studies [11])</li><li>Improving taxonomic assignment quality requires an up-dated fungal database (current databases: Unite, Findley, RTL, TH)</li></ul></td><td>[12,14,16,20,22–24]</td></tr></tbody></table>
### 3. Mycobiome Interactions within the Gut Ecosystem

Similar to gut bacteria, the gut mycobiome contributes to physiological functions and homeostasis throughout a host's lifetime. The effect of the whole microbiome on host health is highlighted by disruptions observed in germ-free mice models [39]. Here we summarize both experimental and clinical data focusing on mycobiome interactions that may be involved in mycobiome-GBA communication through immune and non-immune mediated crosstalk systems, similar to those described in the microbiome-GBA [40].

A first example illustrating the dialogue between fungi and the host immune system is the protective effect of *Saccharomyces boulardii* (the most common probiotic, isolated from fruit) against *Clostridium difficile* colitis. In mice, a prior administration of *S. boulardii* increases the production of immunoglobulin A (IgA), particularly of intestinal anti-toxin IgA [41]. Modulation of the host immune response by *S. boulardii* has also been investigated by Thomas and colleagues [42] who demonstrated that supernatants from *S. boulardii* cultures inhibit the inflammatory response of patients with inflammatory bowel disease (IBD) by inhibiting the activation of T and dendritic cells. The secretion of key pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin(IL)-6 are also reduced [42]. In addition, *S. boulardii* promotes IL-10, an anti-inflammatory cytokine, and epithelial growth factor production [42]. *S. cerevisiae* and *C. albicans* also seem to participate in immune system maturation, inducing functional reprogramming of monocytes and leading to enhanced cytokine production [43,44]. Furthermore, *C. albicans* is able to block monocyte nitric oxide production [44]. This "trained immunity" could be a key factor in the gut immune homeostasis by modulating both the interaction of the host immune system with commensal microorganisms and the host defense against pathogens [45]. Another illustration of this close link between fungi and the immune system is the fungal dysbiosis observed in IBD, an intestinal inflammatory disorder considered as an inappropriate immune reaction against the gut microbiome [46]. Several teams have studied the role of fungal dysbiosis in the pathogenesis of IBD [10,47,48]. To illustrate the fungal impact on IBD, Wheeler and colleagues increased the colitis severity of mice after antifungal administration [48]. Of note, increased plasma levels of (1,3)-β-D-glucan (a major polysaccharide motif of fungal cell walls) are associated with severe colitis in mice [49]. In addition, anti-*S. cerevisiae* antibodies (usually named ASCA) are found to be significantly associated with Crohn disease (CD) in patients [50], which reinforces the concept that fungi are implicated in the inflammatory immune disorder of IBD.

These data highlight the crucial dialogue between the host's innate immune system and the mycobiome, involving many actors (for review see [51]). Among them, Dectin-1 is one of the most important pattern recognition receptors (PRRs) expressed by immune cells that interact with β-glucan [52]. Dectin-1 knockout mice have more severe colitis compared to wild-type; furthermore, polymorphisms of Dectin-1 gene are associated with increased severity of disease in patients with ulcerative colitis (UC) [53].

Interactions between the gut mycobiome and the host system also influence extra-intestinal immune responses. In mice for example, an antifungal administration induces a disruption of the gut mycobiome, characterized by an expansion of *Aspergillus amstelodami*, *Epicoccum nigrum*, and *Wallemia sebi* and a decrease of *Penicillium brevicompactum* and *C. tropicalis*. In parallel, this fungal dysbiosis is clinically associated with a significant increase in allergic airway disease occurrence, which was confirmed by an increased infiltration of inflammatory cells (mainly eosinophils) into animal lungs [48]. Moreover, fungal supplementation in normobiosis mice with these post-antifungal increased strains (*A. amstelodami*, *E. nigrum*, and *W. sebi*, in order to reproduce the observed post-antifungal dysbiosis) replicated effects similar to allergic airway disease occurrence [48]. Taken together, these results indicate that the commensal mycobiome may be a crucial factor in gut and systemic immunological disorders, based on systemic diffusion of either cytokines, fungal products or metabolites, or micromycetous translocation [49].

On the non-immune mediated crosstalk side and focusing on GBA, fungi are able to synthesize and release neurotransmitters, similar to many bacteria. *S. cerevisiae* and *Penicillium chrysogenum*
can produce high concentrations of norepinephrine [54], which is involved in brain activation. This neuromediator increases locomotor activity and aggressive behavior and decreases anxiety reactions. In addition, *C. albicans* is able to produce histamine, another neuromediator involved in appetite regulation, sleep-wake rhythm, and cognitive activity [55]. The direct impact of these mycobiome-produced neuromediators is not entirely clear yet. Even if these neurotransmitters seem unlikely to directly modulate CNS, they could locally act on the enteric nervous system (ENS). Conversely, neuromediators may have an impact on gut fungi. For example, gamma-aminobutyric acid (GABA) is able to increase virulence and germ tube formation of *C. albicans* [56], while serotonin attenuates the *C. albicans* virulence [57].

Finally, inter-kingdom interactions between fungi and bacteria at the gut site may also be implicated in the mycobiome-GBA. While gut bacteria are a known essential actor of the microbiome-GBA [2], mycobiome equilibrium has also been demonstrated as being critical for microbiome stability in a mice model of colitis [49]. In this model, an antifungal exposition induced a fungal diversity decrease along with an increased bacterial diversity, aggravating colitis inflammation and severity [49]. In healthy subjects, Hoffmann and colleagues uncovered specific and significant fungal-bacterial correlations in gut flora [33]. In addition, in the case of bacterial intestinal dysbiosis, such as after antibiotic exposure, commensal fungi or mono-fungal supplementation with *C. albicans* or *S. cerevisiae* can have the same protective benefits as intestinal bacteria in terms of immune system modulation and prevention of mucosal tissue injuries [58]. At molecular levels, *S. boulardii* is able to secrete enzymes, such as proteases or phosphatases, which can inactivate toxins produced by highly inflammatory intestinal pathogens such as *C. difficile* and *E. coli* [59,60]. This yeast also directly inhibits the growth and dissemination of several intestinal pathogens, such as *C. albicans*, *Salmonella typhimurium*, and *Yersinia enterocolitica* [61]. Additionally, β-glucan decreases *E. coli* abundance in animal stools [62], a result suggesting a notable influence of this major fungus wall component on the intestinal growth of *E. coli* and other bacteria, which in turn supports inter-kingdom interactions. On the other hand, *C. albicans* germination is modulated by fatty acids produced locally by bacterial flora [63]. Therefore, we may consider the possibility that the impact of fungi on GBA is due to the local interplay between bacteria and fungi, even though no study has yet focused specifically on this aspect.

These interactions clearly suggest a potential implication of the mycobiome in GBA and, therefore, in various psychiatric and neurological diseases. In the next section, we review evidence of the digestive and neurological aspects of mycobiome influence.

## 4. Mycobiome-Gut-Brain Axis (GBA): Current Evidence from Digestive and Central Nervous Aspects

On the digestive side, many studies have been devoted to the role of gut bacteria in the gut-brain crosstalk. Consistent with this concept, germ-free mice are affected by myelination problems [64] and anxiety-like behavior [65,66], while fecal transplantation modulates this behavior, suggesting once again some strong interactions between the brain and the microbiome [67]. The specific role of gut mycobiome in the communication with the brain is nearly unexplored in the whole microbiome-GBA research field but it is becoming increasingly clear that fungi may have an impact on GBA. Both clinical and experimental data suggest that fungi participate in this dynamic relationship through neuro-immuno-endocrine mediators similar to those described in the microbiome-GBA crosstalk [40]. Numerous evidence consistent with a complex communication network between the gut mycobiome and the brain exists; they are summarized and discussed below.

One main evidence for a key role of the mycobiome in GBA is mycobiome dysbiosis identified in irritable bowel syndrome (IBS). For patients with IBS, a microbiome-GBA disorder is now recognized [68]. It is associated with altered cognitive functions, hypothalamic-pituitary-adrenal axis (HPAA) dysfunctions with lower total cortisol levels, and gut bacterial dysbiosis [69]. In a rat model, antibiotic-induced dysbiosis results in visceral hypersensitivity, a specific clinical trait of rodent IBS models [70]. Furthermore, some studies have shown an efficacy of probiotics in IBS patients [71].
Recently, a mycobiome dysbiosis was also associated with visceral hypersensitivity in a rat model and with human IBS [72], whilst *S. boulardii* supplementation improved gastrointestinal neuromuscular anomalies in a mouse IBS model [73]. These data pave the way for future studies that aim at identifying the specific part of fungi in microbiome-GBA disorders associated with IBS.

Shifts in mycobiome composition have also been reported in various intestinal diseases (for review see [9]), especially in IBD for which an increased fungal load in patients with CD and UC was observed in comparison to healthy controls [10], as well as disease-specific inter-kingdom alterations [10,47,74]. Moreover, depression and psychiatric comorbidities occurred in IBD and have been associated with a systemic inflammation [75]. For example, IL-1 and IL-6 are able to increase cortisol release by HPAA stimulation [76]. Furthermore, patients with depressive disorders exhibit HPAA perturbations with elevated cortisol levels. As previously seen, the mycobiome participates in modulating cytokine production, such as either *C. albicans*, *A. fumigatus* or *S. cerevisiae* with IL-6 [43,77]. Thus, it has been proposed that immune pathways play a critical role here and are mediated by cytokines produced at the gut site, reaching the brain via the bloodstream. These molecules may cross the blood-brain barrier (BBB) and modulate brain area stimulations, particularly the hypothalamus and circumventricular organ stimulations where the BBB is underprovided [78].

In germ-free animals, an increased BBB permeability has been shown, coming from a reduction in tight junction protein expression; this permeability can be decreased after microbial colonization of the mouse digestive tract. BBB permeability is also decreased after gut colonization by short-chain fatty acid (SCFA)-producing bacteria or direct SCFA administration [79]. As fatty acid synthesis fulfills numerous central biological roles in living cells, fatty acid synthase (FAS) is one of the most conserved enzymes of cells including fungal cells. FAS has been described from a variety of yeasts and fungi, such as *S. cerevisiae*, *C. albicans*, other *Candida* species, *Cryptococcus neoformans*, and *Penicillium* species [80]. As fungi such as *S. cerevisiae* or even *Aspergillus fumigatus* are also able to produce short-chain fatty acids [81], we can reasonably hypothesize that the gut mycobiome could use the same pathway; however, no study has explored this hypothesis.

Regarding the central nervous diseases (psychiatric and non-psychiatric ones), the involvement of the human gut mycobiome in the pathophysiology of central nervous diseases has received increased attention in the last few years. The gut mycobiome of an anorexic patient was investigated with culture-dependent and independent approaches. In this case report, the fungal diversity seemed to be decreased with a total of ten different fungal species identified, notably *Aspergillus ruber*, *Penicillium solitum*, *Cladosporium bruhnei* and *Tetratrichomonas* sp. that have not been previously detected in human stools [82].

Another recent study showed for the first time an alteration of the gut mycobiome composition in patients with autism spectrum disorders (ASD), with a trend in increased *Candida* abundance [83]. Given the microbiome influence on ASD based on the increased gastrointestinal problems in this population [84], and given the alteration of BBB permeability and CNS immune response observed in ASD [85] that may be affected by systemic inflammation [86], this over-representation of *Candida* could play a notable role. It may stimulate the host immune response through interactions with specific species such as *Lactobacillus* and may increase IL-22 production [87], a cytokine implicated in the pathogenesis of several autoimmune diseases such as CD and rheumatoid arthritis [88,89]. The *Candida* over-representation may also prevent recovery of a normal flora from a perturbed bacterial flora [90].

Rett syndrome is another progressive neurological genetic disorder often associated with gastrointestinal dysfunctions and constipation. Once again, an increase in the abundance of *Candida* species was described in patients affected by Rett syndrome [91]. In both Rett syndrome and ASD, a predisposition to fungal infections was likewise observed that can, in turn, contribute to systemic responses [92].

Furthermore, a recent study has demonstrated that oral administration of *Candida kefyr* protects mice from developing experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis [93]. This protection was associated with a bacterial microbiome dysbiosis, an increase
of regulatory T cells in mesenteric lymph nodes, and a reduction in T-helper 17 cells on the digestive mucosa.

A fungal dysbiosis was found in individuals with schizophrenia, characterized by an increase in *C. albicans* and *S. cerevisiae* species [94,95]. Moreover, the presence of antibody against *C. albicans* is associated with gastro-intestinal disorders as well as lower scores on cognitive tests in these patients [95]. A supplementation with a probiotic formulation composed of *Lactobacillus rhamnosus* and *Bifidobacterium animalis* significantly reduced blood levels of *C. albicans* antibodies and improved psychiatric symptoms [96].

**5. Concluding Remarks**

It is now well-admitted that the role of the gut microbiome in GBA represents a complex bidirectional system of communication that includes neuro-immuno-endocrine mediators and network pathways between gut mucosa, ENS, and CNS [40,97,98]. In addition to interactions with local bacterial flora and, therefore, acting indirectly on GBA, the gut mycobiome seems to share with the gut microbiome numerous communication processes, which allow us to propose some downward and upward pathways for a mycobiome-GBA in the context of health and disease. These proposed mechanisms of communication between gut mycobiome and GBA are summarized in Figure 1. Furthermore, our growing knowledge on the gut mycobiome, its key role on gut flora equilibrium, and its highly probable role in the whole microbiome-GBA may provide new insight for therapeutic management of neurological and neuropsychiatric disorders such as probiotic administration [73]. In addition, the mycobiome component of gut flora should be systematically taken into account when the gut-microbiome analysis is assessed during clinical trials on GBA.

<figure><img src="image_3.png" /><figcaption>**Figure 1.** Proposed mechanisms of communication between the gut mycobiome and GBA. Figure inspired from [38,95]; for details about fungi-immune system interactions see review [49,96]. Abbreviations: CNS: central nervous system, GBA: gut-brain axis, HPAA: hypothalamic-pituitary-adrenal axis, IL: interleukin, SCFA: short chain fatty acid, TLR: Toll-like receptor.</figcaption></figure>
**Acknowledgments:** Raphael Enaud was supported by a Ph.D. fellowship from the University and Hospital of Bordeaux and has received a research grant from Biocodex. Genoscreen Company provided support in the form of Louise-Eva Vandenborgh's salary. Laurence Delhaes has received a research grant from "Vaincre La Mucoviscidose" (RF20160501626). All these funders had no role in article design, decision to publish, or preparation of the manuscript. The authors thank Lynn Chiu for the English editing.

**Author Contributions:** R.E., L.-E.V., N.C., L.D. constituted together the bibliography. R.E. and L.D. wrote the paper with input and discussion from the other authors. L.-E.V. contributed to Table 1 and N.C. to Figure 1. All authors read and approved the final manuscript.

**Conflicts of Interest:** The authors declare that they have no conflict of interest.

## References

1. Rhee, S.H.; Pothoulakis, C.; Mayer, E.A. Principles and clinical implications of the brain–gut–enteric microbiota axis. *Nat. Rev. Gastroenterol. Hepatol.* **2009**, *6*. [CrossRef] [PubMed]

2. Kennedy, P.J.; Murphy, A.B.; Cryan, J.F.; Ross, P.R.; Dinan, T.G.; Stanton, C. Microbiome in brain function and mental health. *Trends Food Sci. Technol.* **2016**, *57*, 289–301. [CrossRef]

3. Clarke, G.; Grenham, S.; Scully, P.; Fitzgerald, P.; Moloney, R.D.; Shanahan, F.; Dinan, T.G.; Cryan, J.F. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. *Mol. Psychiatry* **2013**, *18*, 666–673. [CrossRef] [PubMed]

4. Buffington, S.A.; Viana Di Prisco, G.; Auchtung, T.A.; Ajami, N.J.; Petrosino, J.F.; Costa-Mattioli, M. Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. *Cell* **2016**, *165*, 1762–1775. [CrossRef] [PubMed]

5. O'Mahony, S.M.; Marchesi, J.R.; Scully, P.; Codling, C.; Ceolho, A.-M.; Quigley, E.M.M.; Cryan, J.F.; Dinan, T.G. Early life stress alters behavior, immunity, and microbiota in rats: Implications for irritable bowel syndrome and psychiatric illnesses. *Biol. Psychiatry* **2009**, *65*, 263–267. [CrossRef] [PubMed]

6. Pirbaglou, M.; Katz, J.; de Souza, R.J.; Stearns, J.C.; Motamed, M.; Ritvo, P. Probiotic supplementation can positively affect anxiety and depressive symptoms: A systematic review of randomized controlled trials. *Nutr. Res.* **2016**, *36*, 889–898. [CrossRef] [PubMed]

7. Zhang, Y.-J.; Li, S.; Gan, R.-Y.; Zhou, T.; Xu, D.-P.; Li, H.-B. Impacts of gut bacteria on human health and diseases. *Int. J. Mol. Sci.* **2015**, *16*, 7493–7519. [CrossRef] [PubMed]

8. Chiu, L.; Bazin, T.; Truchetet, M.-E.; Schaeverbeke, T.; Delhaes, L.; Pradeu, T. Protective Microbiota: From Localized to Long-Reaching Co-Immunity. *Front. Immunol.* **2017**, *8*, 1678. [CrossRef] [PubMed]

9. Huseyin, C.E.; O'Toole, P.W.; Cotter, P.D.; Scanlan, P.D. Forgotten fungi—the gut mycobiome in human health and disease. *FEMS Microbiol. Rev.* **2017**, *41*, 479–511. [CrossRef] [PubMed]

10. Sokol, H.; Leducq, V.; Aschard, H.; Pham, H.-P.; Jegou, S.; Landman, C.; Cohen, D.; Liguori, G.; Bourrier, A.; Nion-Larmurier, I.; et al. Fungal microbiota dysbiosis in IBD. *Gut* **2017**, *66*, 1039–1048. [CrossRef] [PubMed]

11. NIH HMP Working Group; Peterson, J.; Garges, S.; Giovanni, M.; McInnes, P.; Wang, L.; Schloss, J.A.; Bonazzi, V.; McEwen, J.E.; Wetterstrand, K.A.; et al. The NIH Human Microbiome Project. *Genome Res.* **2009**, *19*, 2317–2323. [CrossRef] [PubMed]

12. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T.; et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* **2010**, *464*, 59–65. [CrossRef] [PubMed]

13. Nash, A.K.; Auchtung, T.A.; Wong, M.C.; Smith, D.P.; Gesell, J.R.; Ross, M.C.; Stewart, C.J.; Metcalf, G.A.; Muzny, D.M.; Gibbs, R.A.; et al. The gut mycobiome of the Human Microbiome Project healthy cohort. *Microbiome* **2017**, *5*, 153. [CrossRef] [PubMed]

14. Huffnagle, G.B.; Noverr, M.C. The emerging world of the fungal microbiome. *Trends Microbiol.* **2013**, *21*, 334–341. [CrossRef] [PubMed]

15. Nguyen, L.D.N.; Viscogliosi, E.; Delhaes, L. The lung mycobiome: An emerging field of the human respiratory microbiome. *Front. Microbiol.* **2015**, *6*, 89. [CrossRef] [PubMed]

16. Vesty, A.; Biswas, K.; Taylor, M.W.; Gear, K.; Douglas, R.G. Evaluating the Impact of DNA Extraction Method on the Representation of Human Oral Bacterial and Fungal Communities. *PLoS ONE* **2017**, *12*, e0169877. [CrossRef] [PubMed]
17. Halwachs, B.; Madhusudhan, N.; Krause, R.; Nilsson, R.H.; Moissl-Eichinger, C.; Högenauer, C.; Thallinger, G.G.; Gorkiewicz, G. Critical Issues in Mycobiota Analysis. *Front. Microbiol.* **2017**, *8*, 180. [CrossRef] [PubMed]

18. Lindahl, B.D.; Nilsson, R.H.; Tedersoo, L.; Abarenkov, K.; Carlsen, T.; Kjøller, R.; Kõljalg, U.; Pennanen, T.; Rosendahl, S.; Stenlid, J.; Kauserud, H. Fungal community analysis by high-throughput sequencing of amplified markers—A user’s guide. *New Phytol.* **2013**, *199*, 288–299. [CrossRef] [PubMed]

19. De Filippis, F.; Laiola, M.; Blaiotta, G.; Ercolini, D. Different Amplicon Targets for Sequencing-Based Studies of Fungal Diversity. *Appl. Environ. Microbiol.* **2017**, *83*. [CrossRef] [PubMed]

20. Nguyen, L.D.N.; Deschaght, P.; Merlin, S.; Loywick, A.; Audebert, C.; Van Daele, S.; Viscogliosi, E.; Vaneechoutte, M.; Delhaes, L. Effects of Propidium Monoazide (PMA) Treatment on Mycobiome and Bacteriome Analysis of Cystic Fibrosis Airways during Exacerbation. *PLoS ONE* **2016**, *11*, e0168860. [CrossRef] [PubMed]

21. Tang, J.; Iliev, I.D.; Brown, J.; Underhill, D.M.; Funari, V.A. Mycobiome: Approaches to analysis of intestinal fungi. *J. Immunol. Methods* **2015**, *421*, 112–121. [CrossRef] [PubMed]

22. Marsh, A.J.; O'Sullivan, O.; Hill, C.; Ross, R.P.; Cotter, P.D. Sequence-based analysis of the bacterial and fungal compositions of multiple kombucha (tea fungus) samples. *Food Microbiol.* **2014**, *38*, 171–178. [CrossRef] [PubMed]

23. Schoch, C.L.; Robbertse, B.; Robert, V.; Vu, D.; Cardinali, G.; Irinyi, L.; Meyer, W.; Nilsson, R.H.; Hughes, K.; Miller, A.N.; et al. Finding needles in haystacks: Linking scientific names, reference specimens and molecular data for Fungi. *Database J. Biol. Databases Curation* **2014**, *2014*. [CrossRef] [PubMed]

24. White, J.R.; Maddox, C.; White, O.; Angiuoli, S.V.; Fricke, W.F. CloVR-ITS: Automated internal transcribed spacer amplicon sequence analysis pipeline for the characterization of fungal microbiota. *Microbiome* **2013**, *1*, 6. [CrossRef] [PubMed]

25. Gdanetz, K.; Benucci, G.M.N.; Vande Pol, N.; Bonito, G. CONSTAX: A tool for improved taxonomic resolution of environmental fungal ITS sequences. *BMC Bioinform.* **2017**, *18*, 538. [CrossRef] [PubMed]

26. Pashley, C.H.; Fairs, A.; Free, R.C.; Wardlaw, A.J. DNA analysis of outdoor air reveals a high degree of fungal diversity, temporal variability, and genera not seen by spore morphology. *Fungal Biol.* **2012**, *116*, 214–224. [CrossRef] [PubMed]

27. Denning, D.W.; Pashley, C.; Hartl, D.; Wardlaw, A.; Godet, C.; Del Giacco, S.; Delhaes, L.; Sergejeva, S. Fungal allergy in asthma-state of the art and research needs. *Clin. Transl. Allergy* **2014**, *4*, 14. [CrossRef] [PubMed]

28. Delhaes, L.; Monchy, S.; Fréalle, E.; Hubans, C.; Salleron, J.; Leroy, S.; Prevotat, A.; Wallet, F.; Wallaert, B.; Dei-Cas, E.; et al. The airway microbiota in cystic fibrosis: A complex fungal and bacterial community-implications for therapeutic management. *PLoS ONE* **2012**, *7*, e36313. [CrossRef] [PubMed]

29. Seed, P.C. The human mycobiome. *Cold Spring Harb. Perspect. Med.* **2014**, *5*, a019810. [CrossRef] [PubMed]

30. Heisel, T.; Podgorski, H.; Staley, C.M.; Knights, D.; Sadowsky, M.J.; Gale, C.A. Complementary Amplicon-Based Genomic Approaches for the Study of Fungal Communities in Humans. *PLoS ONE* **2015**, *10*. [CrossRef] [PubMed]

31. Fujimura, K.E.; Sitarik, A.R.; Havstad, S.; Lin, D.L.; Levan, S.; Fadrosh, D.; Panzer, A.R.; LaMere, B.; Rackaityte, E.; Lukacs, N.W.; et al. Neonatal gut microbiota associates with childhood multi-sensitized atopy and T-cell differentiation. *Nat. Med.* **2016**, *22*, 1187–1191. [CrossRef] [PubMed]

32. Strati, F.; Di Paola, M.; Stefanini, I.; Albanese, D.; Rizzetto, L.; Lionetti, P.; Calabrò, A.; Jousson, O.; Donati, C.; Cavalieri, D.; De Filippo, C. Age and Gender Affect the Composition of Fungal Population of the Human Gastrointestinal Tract. *Front. Microbiol.* **2016**, *7*. [CrossRef] [PubMed]

33. Hoffmann, C.; Dollive, S.; Grunberg, S.; Chen, J.; Li, H.; Wu, G.D.; Lewis, J.D.; Bushman, F.D. Archaea and fungi of the human gut microbiome: Correlations with diet and bacterial residents. *PLoS ONE* **2013**, *8*, e66019. [CrossRef] [PubMed]

34. Hallen-Adams, H.E.; Suhr, M.J. Fungi in the healthy human gastrointestinal tract. *Virulence* **2017**, *8*, 352–358. [CrossRef] [PubMed]

35. Sam, Q.H.; Chang, M.W.; Chai, L.Y.A. The Fungal Mycobiome and Its Interaction with Gut Bacteria in the Host. *Int. J. Mol. Sci.* **2017**, *18*, 330. [CrossRef] [PubMed]

36. Hibbett, D.S.; Binder, M.; Bischoff, J.F.; Blackwell, M.; Cannon, P.F.; Eriksson, O.E.; Huhndorf, S.; James, T.; Kirk, P.M.; Lücking, R.; et al. A higher-level phylogenetic classification of the Fungi. *Mycol. Res.* **2007**, *111*, 509–547. [CrossRef] [PubMed]
37. Hallen-Adams, H.E.; Kachman, S.D.; Kim, J.; Legge, R.M.; Martínez, I. Fungi inhabiting the healthy human gastrointestinal tract: A diverse and dynamic community. *Fungal Ecol.* **2015**, *15*, 9–17. [CrossRef]

38. Mar Rodríguez, M.; Pérez, D.; Javier Chaves, F.; Esteve, E.; Marin-Garcia, P.; Xifra, G.; Vendrell, J.; Jové, M.; Pamplona, R.; Ricart, W.; et al. Obesity changes the human gut mycobiome. *Sci. Rep.* **2015**, *5*, 14600. [CrossRef] [PubMed]

39. Bhattarai, Y.; Kashyap, P.C. Germ-Free Mice Model for Studying Host-Microbial Interactions. *Methods Mol. Biol.* **2016**, *1438*, 123–135. [CrossRef] [PubMed]

40. Carabotti, M.; Scirocco, A.; Maselli, M.A.; Severi, C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. *Ann. Gastroenterol.* **2015**, *28*, 203–209. [PubMed]

41. Qamar, A.; Aboudola, S.; Warny, M.; Michetti, P.; Pothoulakis, C.; LaMont, J.T.; Kelly, C.P. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. *Infect. Immun.* **2001**, *69*, 2762–2765. [CrossRef] [PubMed]

42. Thomas, S.; Metzke, D.; Schmitz, J.; Dörffel, Y.; Baumgart, D.C. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2011**, *301*, G1083–1092. [CrossRef] [PubMed]

43. Rizzetto, L.; Ifrim, D.C.; Moretti, S.; Tocci, N.; Cheng, S.-C.; Quintin, J.; Renga, G.; Oikonomou, V.; De Filippo, C.; Weil, T.; et al. Fungal Chitin Induces Trained Immunity in Human Monocytes during Cross-talk of the Host with Saccharomyces cerevisiae. *J. Biol. Chem.* **2016**, *291*, 7961–7972. [CrossRef] [PubMed]

44. Quintin, J.; Saeed, S.; Martens, J.H.A.; Giamarellos-Bourboulis, E.J.; Ifrim, D.C.; Logie, C.; Jacobs, L.; Jansen, T.; Kullberg, B.-J.; Wijmenga, C.; et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. *Cell Host Microbe* **2012**, *12*, 223–232. [CrossRef] [PubMed]

45. Wagener, J.; Malireddi, R.K.S.; Lenardon, M.D.; Köberle, M.; Vautier, S.; MacCallum, D.M.; Biedermann, T.; Schaller, M.; Netea, M.G.; Kanneganti, T.-D.; et al. Fungal chitin dampens inflammation through IL-10 induction mediated by NOD2 and TLR9 activation. *PLoS Pathog.* **2014**, *10*, e1004050. [CrossRef] [PubMed]

46. Nishida, A.; Inoue, R.; Inatomi, O.; Bamba, S.; Naito, Y.; Andoh, A. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin. J. Gastroenterol.* **2017**. [CrossRef] [PubMed]

47. Ott, S.J.; Kühbacher, T.; Musfeldt, M.; Rosenstiel, P.; Hellmig, S.; Rehman, A.; Drews, O.; Weichert, W.; Timmis, K.N.; Schreiber, S. Fungi and inflammatory bowel diseases: Alterations of composition and diversity. *Scand. J. Gastroenterol.* **2008**, *43*, 831–841. [CrossRef] [PubMed]

48. Wheeler, M.L.; Limon, J.J.; Bar, A.S.; Leal, C.A.; Gargus, M.; Tang, J.; Brown, J.; Funari, V.A.; Wang, H.L.; Crother, T.R.; et al. Immunological Consequences of Intestinal Fungal Dysbiosis. *Cell Host Microbe* **2016**, *19*, 865–873. [CrossRef] [PubMed]

49. Qiu, X.; Zhang, F.; Yang, X.; Wu, N.; Jiang, W.; Li, X.; Li, X.; Liu, Y. Changes in the composition of intestinal fungi and their role in mice with dextran sulfate sodium-induced colitis. *Sci. Rep.* **2015**, *5*, 10416. [CrossRef] [PubMed]

50. McKenzie, H.; Main, J.; Pennington, C.R.; Parratt, D. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. *Gut* **1990**, *31*, 536–538. [CrossRef] [PubMed]

51. Wheeler, M.L.; Limon, J.J.; Underhill, D.M. Immunity to Commensal Fungi: Detente and Disease. *Annu. Rev. Pathol.* **2017**, *12*, 359–385. [CrossRef] [PubMed]

52. Brown, G.D.; Gordon, S. Fungal beta-glucans and mammalian immunity. *Immunity* **2003**, *19*, 311–315. [CrossRef]

53. Iliev, I.D.; Funari, V.A.; Taylor, K.D.; Nguyen, Q.; Reyes, C.N.; Strom, S.P.; Brown, J.; Becker, C.A.; Fleshner, P.R.; Dubinsky, M.; et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. *Science* **2012**, *336*, 1314–1317. [CrossRef] [PubMed]

54. Tsavkelova, E.A.; Botvinko, I.V.; Kudrin, V.S.; Oleskin, A.V. Detection of neurotransmitter amines in microorganisms with the use of high-performance liquid chromatography. *Dokl. Biochem. Proc. Acad. Sci. USSR Biochem. Sect.* **2000**, *372*, 115–117.

55. Voropaeva, E.A. Resistance to antibiotics and histamine production at the bacteria, isolated from the stomatopharynx of the children with bronchial asthma. *Antibiot. Khimioterapiia Antibiot. Chemoterapy Sic* **2002**, *47*, 8–13.
56. Reyes-García, M.G.; García-Tamayo, F.; Hernández-Hernández, F. Gamma-aminobutyric acid (GABA) increases in vitro germ-tube formation and phospholipase B1 mRNA expression in Candida albicans. *Mycoscience* **2012**, *53*, 36–39. [CrossRef]

57. Mayr, A.; Hinterberger, G.; Dierich, M.P.; Lass-Flörl, C. Interaction of serotonin with Candida albicans selectively attenuates fungal virulence in vitro. *Int. J. Antimicrob. Agents* **2005**, *26*, 335–337. [CrossRef] [PubMed]

58. Jiang, T.T.; Shao, T.-Y.; Ang, W.X.G.; Kinder, J.M.; Turner, L.H.; Pham, G.; Whitt, J.; Alenghat, T.; Way, S.S. Commensal Fungi Recapitulate the Protective Benefits of Intestinal Bacteria. *Cell Host Microbe* **2017**, *22*, 809–816. [CrossRef] [PubMed]

59. Castagliuolo, I.; Riegler, M.F.; Valenick, L.; LaMont, J.T.; Pothoulakis, C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. *Infect. Immun.* **1999**, *67*, 302–307. [CrossRef]

60. Buts, J.-P.; Dekeyser, N.; Stilmant, C.; Delem, E.; Smets, F.; Sokal, E. Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. *Pediatr. Res.* **2006**, *60*, 24–29. [CrossRef] [PubMed]

61. Ducluzeau, R.; Bensaada, M. Comparative effect of a single or continuous administration of "Saccharomyces boulardii" on the establishment of various strains of "candida" in the digestive tract of gnotobiotic mice. *Ann. Microbiol.* **1982**, *133*, 491–501. [PubMed]

62. Zhou, T.X.; Jung, J.H.; Zhang, Z.F.; Kim, I.H. Effect of dietary β-glucan on growth performance, fecal microbial shedding and immunological responses after lipopolysaccharide challenge in weaned pigs. *Anim. Feed Sci. Technol.* **2013**, *179*, 85–92. [CrossRef]

63. Noverr, M.C.; Huffnagle, G.B. Regulation of Candida albicans morphogenesis by fatty acid metabolites. *Infect. Immun.* **2004**, *72*, 6206–6210. [CrossRef] [PubMed]

64. Hoban, A.E.; Stilling, R.M.; Ryan, F.J.; Shanahan, F.; Dinan, T.G.; Claesson, M.J.; Clarke, G.; Cryan, J.F. Regulation of prefrontal cortex myelination by the microbiota. *Transl. Psychiatry* **2016**, *6*, e774. [CrossRef] [PubMed]

65. Neufeld, K.M.; Kang, N.; Bienenstock, J.; Foster, J.A. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. *Neurogastroenterol. Motil.* **2011**, *23*. [CrossRef] [PubMed]

66. Diaz Heijtz, R.; Wang, S.; Anuar, F.; Qian, Y.; Björkholm, B.; Samuelsson, A.; Hibberd, M.L.; Forssberg, H.; Pettersson, S. Normal gut microbiota modulates brain development and behavior. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 3047–3052. [CrossRef] [PubMed]

67. Bercik, P.; Denou, E.; Collins, J.; Jackson, W.; Lu, J.; Jury, J.; Deng, Y.; Blennerhassett, P.; Macri, J.; McCoy, K.D.; et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. *Gastroenterology* **2011**, *141*, 599–609. [CrossRef] [PubMed]

68. Kennedy, P.J.; Cryan, J.F.; Dinan, T.G.; Clarke, G. Irritable bowel syndrome: A microbiome-gut-brain axis disorder? *World J. Gastroenterol.* **2014**, *20*, 14105–14125. [CrossRef] [PubMed]

69. Jeffery, I.B.; O'Toole, P.W.; Öhman, L.; Claesson, M.J.; Deane, J.; Quigley, E.M.M.; Simrén, M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. *Gut* **2012**, *61*, 997–1006. [CrossRef] [PubMed]

70. O'Mahony, S.M.; Felice, V.D.; Nally, K.; Savignac, H.M.; Claesson, M.J.; Scully, P.; Woznicki, J.; Hyland, N.P.; Shanahan, F.; Quigley, E.M.; et al. Disturbance of the gut microbiota in early-life selectively affects visceral pain in adulthood without impacting cognitive or anxiety-related behaviors in male rats. *Neuroscience* **2014**, *277*, 885–901. [CrossRef] [PubMed]

71. Didari, T.; Mozaffari, S.; Nikfar, S.; Abdollahi, M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. *World J. Gastroenterol.* **2015**, *21*, 3072–3084. [CrossRef] [PubMed]

72. Botschuijver, S.; Roeselers, G.; Levin, E.; Jonkers, D.M.; Welting, O.; Heinsbroek, S.E.M.; de Weerd, H.H.; Boekhout, T.; Fornai, M.; Masclee, A.A.; et al. Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats. *Gastroenterology* **2017**, *153*, 1026–1039. [CrossRef] [PubMed]

73. Brun, P.; Scarpa, M.; Marchiori, C.; Sarasin, G.; Caputi, V.; Porzionato, A.; Giron, M.C.; Palù, G.; Castagliuolo, I. Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS. *PLoS ONE* **2017**, *12*. [CrossRef]
74. Hoarau, G.; Mukherjee, P.K.; Gower-Rousseau, C.; Hager, C.; Chandra, J.; Retuerto, M.A.; Neut, C.; Vermeire, S.; Clemente, J.; Colombel, J.F.; et al. Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn's Disease. *mBio* **2016**, 7. [CrossRef] [PubMed]

75. Abautret-Daly, Á.; Dempsey, E.; Parra-Blanco, A.; Medina, C.; Harkin, A. Gut-brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease. *Acta Neuropsychiatr.* **2017**, 1-22. [CrossRef] [PubMed]

76. Dantzer, R. Cytokine, sickness behavior, and depression. *Immunol. Allergy Clin. N. Am.* **2009**, *29*, 247–264.
[CrossRef] [PubMed]

77. Czakai, K.; Leonhardt, I.; Dix, A.; Bonin, M.; Linde, J.; Einsele, H.; Kurzai, O.; Loeffler, J. Krüppel-like Factor 4 modulates interleukin-6 release in human dendritic cells after in vitro stimulation with Aspergillus fumigatus and Candida albicans. *Sci. Rep.* **2016**, *6*, 27990. [CrossRef] [PubMed]

78. El Aidy, S.; Dinan, T.G.; Cryan, J.F. Immune modulation of the brain-gut-microbe axis. *Front. Microbiol.* **2014**, *5*, 146. [CrossRef] [PubMed]

79. Braniste, V.; Al-Asmakh, M.; Kowal, C.; Anuar, F.; Abbaspour, A.; Tóth, M.; Korecka, A.; Bakocevic, N.; Ng, L.G.; Guan, N.L.; et al. The gut microbiota influences blood-brain barrier permeability in mice. *Sci. Transl. Med.* **2014**, *6*, 263ra158. [CrossRef] [PubMed]

80. Schweizer, E.; Hofmann, J. Microbial type I fatty acid synthases (FAS): Major players in a network of cellular FAS systems. *Microbiol. Mol. Biol. Rev.* **MMBR 2004**, *68*, 501–517. [CrossRef] [PubMed]

81. Baltierra-Trejo, E.; Sánchez-Yáñez, J.M.; Buenrostro-Delgado, O.; Márquez-Benavides, L. Production of short-chain fatty acids from the biodegradation of wheat straw lignin by Aspergillus fumigatus. *Bioresour. Technol.* **2015**, *196*, 418–425. [CrossRef] [PubMed]

82. Gouba, N.; Raoult, D.; Drancourt, M. Gut microeukaryotes during anorexia nervosa: A case report. *BMC Res. Notes* **2014**, *7*, 33. [CrossRef] [PubMed]

83. Strati, F.; Cavalieri, D.; Albanese, D.; De Felice, C.; Donati, C.; Hayek, J.; Jousson, O.; Leoncini, S.; Renzi, D.; Calabrò, A.; De Filippo, C. New evidences on the altered gut microbiota in autism spectrum disorders. *Microbiome* **2017**, *5*, 24. [CrossRef] [PubMed]

84. Krajmalnik-Brown, R.; Lozupone, C.; Kang, D.-W.; Adams, J.B. Gut bacteria in children with autism spectrum disorders: Challenges and promise of studying how a complex community influences a complex disease. *Microb. Ecol. Health Dis.* **2015**, *26*, 26914. [CrossRef] [PubMed]

85. Onore, C.; Careaga, M.; Ashwood, P. The role of immune dysfunction in the pathophysiology of autism. *Brain Behav. Immun.* **2012**, *26*, 383–392. [CrossRef] [PubMed]

86. Berer, K.; Krishnamoorthy, G. Commensal gut flora and brain autoimmunity: A love or hate affair? *Acta Neuropathol.* **2012**, *123*, 639–651. [CrossRef] [PubMed]

87. Zelante, T.; Iannitti, R.G.; Cunha, C.; De Luca, A.; Giovannini, G.; Pieraccini, G.; Zecchi, R.; D'Angelo, C.; Massi-Benedetti, C.; Fallarino, F.; et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity* **2013**, *39*, 372–385. [CrossRef] [PubMed]

88. Wolk, K.; Witte, E.; Hoffmann, U.; Doecke, W.-D.; Endesfelder, S.; Asadullah, K.; Sterry, W.; Volk, H.-D.; Wittig, B.M.; Sabat, R. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: A potential systemic role of IL-22 in Crohn's disease. *J. Immunol.* **2007**, *178*, 5973–5981. [CrossRef]

89. Ikeuchi, H.; Kuroiwa, T.; Hiramatsu, N.; Kaneko, Y.; Hiromura, K.; Ueki, K.; Nojima, Y. Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. *Arthritis Rheum.* **2005**, *52*, 1037–1046. [CrossRef] [PubMed]

90. Erb Downward, J.R.; Falkowski, N.R.; Mason, K.L.; Muraglia, R.; Huffnagle, G.B. Modulation of post-antibiotic bacterial community reassembly and host response by Candida albicans. *Sci. Rep.* **2013**, *3*, 2191. [CrossRef] [PubMed]

91. Strati, F.; Cavalieri, D.; Albanese, D.; De Felice, C.; Donati, C.; Hayek, J.; Jousson, O.; Leoncini, S.; Pindo, M.; Renzi, D.; et al. Altered gut microbiota in Rett syndrome. *Microbiome* **2016**, *4*, 41. [CrossRef] [PubMed]

92. Underhill, D.M.; Iliev, I.D. The mycobiota: Interactions between commensal fungi and the host immune system. *Nat. Rev. Immunol.* **2014**, *14*, 405–416. [CrossRef] [PubMed]

93. Takata, K.; Tomita, T.; Okuno, T.; Kinoshita, M.; Koda, T.; Honorat, J.A.; Takei, M.; Hagihara, K.; Sugimoto, T.; Mochizuki, H.; et al. Dietary Yeasts Reduce Inflammation in Central Nerve System via Microflora. *Ann. Clin. Transl. Neurol.* **2015**, *2*, 56–66. [CrossRef] [PubMed]
94. Severance, E.G.; Alaedini, A.; Yang, S.; Halling, M.; Gressitt, K.L.; Stallings, C.R.; Origoni, A.E.; Vaughan, C.; Khushalani, S.; Leweke, F.M.; et al. Gastrointestinal inflammation and associated immune activation in schizophrenia. *Schizophr. Res.* **2012**, *138*, 48–53. [CrossRef] [PubMed]

95. Severance, E.G.; Gressitt, K.L.; Stallings, C.R.; Katsafanas, E.; Schweinfurth, L.A.; Savage, C.L.; Adamos, M.B.; Sweeney, K.M.; Origoni, A.E.; Khushalani, S.; et al. Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorder. *NPJ Schizophr.* **2016**, *2*, 16018. [CrossRef] [PubMed]

96. Severance, E.G.; Gressitt, K.L.; Stallings, C.R.; Katsafanas, E.; Schweinfurth, L.A.; Savage, C.L.G.; Adamos, M.B.; Sweeney, K.M.; Origoni, A.E.; Khushalani, S.; et al. Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study. *Brain Behav. Immun.* **2017**, *62*, 41–45. [CrossRef] [PubMed]

97. Bonaz, B.; Bazin, T.; Pellissier, S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. *Front. Neurosci.* **2018**, *12*. [CrossRef] [PubMed]

98. Foster, J.A.; Rinaman, L.; Cryan, J.F. Stress & the gut-brain axis: Regulation by the microbiome. *Neurobiol. Stress* **2017**, *7*, 124–136. [CrossRef] [PubMed]

<figure><img src="image_4.png" /></figure>

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).